Tocilizumab for giant cell arteritis-Reference-Cited by-同舟云学术

Tocilizumab for giant cell arteritis

Published:2022-05-13 Issue:5 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Antonio Aileen A¹,Santos Ronel N¹,Abariga Samuel A²

Affiliation:

1. Hauenstein Neurosciences, Mercy Health Saint Mary's; Grand Rapids Michigan USA

2. Department of Ophthalmology; University of Colorado Anschutz Medical Campus; Denver Colorado USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference58 articles.

1. Birchwood C Tuckwell K Dimonaco S Klearman M Collinson N Stone JH Tocilizumab in patients with giant cell arteritis: analysis of new-onset and relapsing subgroups from a randomized, double-blind, placebo-controlled, phase 3 trial Investigative Ophthalmology & Visual Science 2017 58 8

2. Haskova Z Strand V Dimonaco S Tuckwell K Klearman M Collinson N Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomized controlled trial Investigative Ophthalmology & Visual Science 2018 59 9

3. Mollan SP Tuckwell K Dimonaco S Klearman M Collinson N Stone JH Tocilizumab in patients with giant cell arteritis: results from a Phase 3 randomized controlled trial Journal of Headache and Pain 2018 19 10.1186/s10194-018-0900-0

4. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab;Stone;Arthritis & Rheumatology,2019

5. Trial of tocilizumab in giant-cell arteritis;Stone;New England Journal of Medicine,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How beneficial and safe is tocilizumab for patients with giant cell arteritis? A Cochrane Review summary with commentary;International Journal of Rheumatic Diseases;2022-07-07